In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their
Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De